The US Food and Drug Administration (FDA) has granted 510(k) clearance to Seventh Sense Biosystems' (7SBio) new push-button blood collection device TAP.
The new device is claimed to provide a virtually painless, simple and fast blood collection process and eliminates the need for insertion of a long needle into a vein or lancet to a fingertip.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
TAP can be placed on the upper arm and blood collection starts with a simple press of a button and takes about 2-3 minutes to be complete.
7SBio chief executive officer Howard Weisman said: "No one likes getting blood drawn, but blood is the single-most important source of medical information in healthcare today, with about 90% of all diagnostic information coming from blood and its components.
"TAP has the potential to transform blood collection from an inconvenient, stressful, and painful experience to one people can do themselves anywhere, making health monitoring much easier for both healthcare professionals and patients."
The current clearance allows the use of the device to collect capillary blood for hemoglobin A1c (HbA1c) testing to monitor blood sugar levels in diabetic or pre-diabetic patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt is expecyed that TAP can facilitate efficient blood collection in reference labs, hospitals, retail pharmacies, doctors' offices, wellness screenings, molecular diagnostics testing, athlete monitoring and clinical trials.
7SBio is currently working with the FDA to expand TAP's clearance for use in additional tests.
The firm also intends to develop and commercialise different versions of the device that would allow users to collect blood anywhere and anytime.
